ReviewBioMed research international2026
A Review of the Clinical Utility of Tubule-Specific Biomarkers in Sickle Cell Nephropathy.
Review in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell nephropathy affects about 30%-50% of individuals living with sickle cell disease (SCD), raising the risk of mortality in this population. Traditional renal markers, such as serum creatinine and glomerular filtration rate, fail to detect renal damage until substantial injury occurs. However, growing evidence suggests tubular injury precedes glomerular damage, offering opportunities for earlier intervention through novel biomarkers that detect subclinical renal stress before albuminuria onset. In this narrative review, we evaluated kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, N-acetyl-β-D-glucosaminidase, transforming growth factor-β, liver-type fatty acid binding protein, and monocyte chemoattractant protein-1 as early indicators of renal damage in individuals with SCD. Additionally, we examine the effect of existing SCD therapy on these biomarkers, highlighting their clinical relevance in sickle cell nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.